Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fabhalta (iptacopan) post-marketing specified drug-use survey in C3 glomerulopathy
jRCT2031250387Recruiting
- Sponsor
- Novartis
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iptacopan in Complement 3 glomerulopathy (C3G), sponsored by Novartis. Primary endpoint: Infection-related adverse events and reactions during Fabhalta treatment. Started Jul 2025; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on jRCT2031250387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250387.